VBI Vaccines, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced that the independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent GBM.